Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron and Other Variants in Serum From Children With Vaccination-Induced Myocarditis

Fatema Tuz Zahra; Gabrielle Grubbs; Kirsten Dummer; Adriana H Tremoulet; Chisato Shimizu; Jane C Burns; Surender Khurana

doi:10.1093/cid/ciac323

Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron and Other Variants in Serum From Children With Vaccination-Induced Myocarditis

Clin Infect Dis. 2022 Oct 29;75(9):1645-1648. doi: 10.1093/cid/ciac323.

Authors

Fatema Tuz Zahra¹, Gabrielle Grubbs¹, Kirsten Dummer², Adriana H Tremoulet², Chisato Shimizu², Jane C Burns², Surender Khurana¹

Affiliations

¹ Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, Maryland, USA.
² Kawasaki Disease Research Center, Rady Children's Hospital and Department of Pediatrics, UCSD School of Medicine, La Jolla, California, USA.

Abstract

Our study demonstrates that children who developed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination-induced myocarditis and may not receive another vaccination, could be susceptible to infection with Omicron and emerging variants. We observed higher neutralizing antibody titers in myocarditis patients vs. healthy vaccinated children, but significantly lower neutralization titers against Omicron in both groups.

Keywords: COVID-19; Omicron; SARS-CoV-2; myocarditis; vaccination.

Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2022.

Publication types

Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.

MeSH terms

Antibodies, Neutralizing
Antibodies, Viral
COVID-19* / prevention & control
Child
Humans
Myocarditis* / etiology
Neutralization Tests
SARS-CoV-2
Vaccination / adverse effects

Substances

Antibodies, Viral
Antibodies, Neutralizing

Abstract

Publication types

MeSH terms

Substances

Grants and funding